Paris – Sanofi-Aventis’ pursuit of US-biotech company Genzyme was still pending as the French drugmaker entered a strategic alliance for research in personalised medicine with Scripps Genomic Medicine, part of the Scripps Health hospital system in San Diego (California). Sanofi-Aventis’ R&D unit will provide undisclosed funding for up to three grants there each year, offering flexible financing for innovative research proposed by Scripps scientists. In exchange, the company will receive non-exclusive rights to any new tests or other research tools developed under the grants, as well as preferred access to Scripps laboratory facilities and technologies. In 2010 -2011, the research will focus on diabetes and ageing diseases. Sanofi will also have access to Scripps research programms through an annual research symposium aimed at ongoing scientific exchange.